Second, the median follow-up duration was 59 months, and the RFS rate observed in our study was 89%, which underscores the generally favorable prognosis for premenopausal patients with low-risk endometrial cancer, even with elevated CA125 levels. This evidence concerns the gene MUC16 and endometrial cancer.